Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 1
2010 1
2011 1
2013 2
2014 5
2015 4
2016 1
2017 2
2018 5
2019 5
2020 4
2021 7
2022 8
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean chonglin yang (60 results)?
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS. Zhu F, et al. Among authors: yang c. Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26. Lancet Respir Med. 2022. PMID: 35644168 Free PMC article. Clinical Trial.
Optimizing T Cell-Based Therapy for Glioblastoma.
Karachi A, Dastmalchi F, Nazarian S, Huang J, Sayour EJ, Jin L, Yang C, Mitchell DA, Rahman M. Karachi A, et al. Among authors: yang c. Front Immunol. 2021 Aug 5;12:705580. doi: 10.3389/fimmu.2021.705580. eCollection 2021. Front Immunol. 2021. PMID: 34421912 Free PMC article. Review.
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.
DiVita Dean B, Wildes T, Dean J, Yegorov O, Yang C, Shin D, Francis C, Figg JW, Sebastian M, Font LF, Jin D, Reid A, Moore G, Fernandez B, Wummer B, Kuizon C, Mitchell D, Flores CT. DiVita Dean B, et al. Among authors: yang c. J Immunother Cancer. 2023 Feb;11(2):e004805. doi: 10.1136/jitc-2022-004805. J Immunother Cancer. 2023. PMID: 36750252 Free PMC article.
Prognostic Pathways Guide Drug Indications in Pan-Cancers.
Meng F, Zhang K, Yang C, Zhang K, Xu Q, Ren R, Zhou Y, Sun Y, Peng Y, Li Y, Guo H, Ren Y, Zhao Z. Meng F, et al. Among authors: yang c. Front Oncol. 2022 Mar 14;12:849552. doi: 10.3389/fonc.2022.849552. eCollection 2022. Front Oncol. 2022. PMID: 35372084 Free PMC article.
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Chu K, Bi ZF, Huang WJ, Li YF, Zhang L, Yang CL, Jiang HM, Zang X, Chen Q, Liu DL, Pan HX, Huang Y, Zheng FZ, Zhang QF, Sun G, Su YY, Huang SJ, Pan HR, Wu T, Hu YM, Zhang J, Zhu FC, Xia NS. Chu K, et al. Lancet Reg Health West Pac. 2023 Mar 13;34:100731. doi: 10.1016/j.lanwpc.2023.100731. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283969 Free PMC article.
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Hu YM, Bi ZF, Zheng Y, Zhang L, Zheng FZ, Chu K, Li YF, Chen Q, Quan JL, Hu XW, Huang XC, Zhu KX, Wang-Jiang YH, Jiang HM, Zang X, Liu DL, Yang CL, Pan HX, Zhang QF, Su YY, Huang SJ, Sun G, Huang WJ, Huang Y, Wu T, Zhang J, Xia NS. Hu YM, et al. Sci Bull (Beijing). 2023 Oct 30;68(20):2448-2455. doi: 10.1016/j.scib.2023.09.020. Epub 2023 Sep 19. Sci Bull (Beijing). 2023. PMID: 37743201 Free article. Clinical Trial.
58 results